{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:30:22Z","timestamp":1786347022980,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Research and Development Region Kronoberg"},{"name":"Region Stockholm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To analyse the prevalence of obesity and its impact on long-term cardiovascular outcomes in patients with myocardial infarction (MI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with MI registered in SWEDEHEART between 2010 and 2021 were followed through December 2021 (mean follow-up time 6 years). Associated risk of adverse events in WHO body mass index (BMI) strata was assessed in adjusted Cox proportional hazards models, stratified by diabetes status (reference: normal BMI without diabetes). Of 124 360 patients, 21% had diabetes. Obesity was more common among patients with diabetes (37% vs. 20%). The highest risk of mortality and major cardiovascular events (MACE; all-cause death, MI, stroke, or heart failure) was observed in those with Class 3 obesity and diabetes [HR 2.15 (95% CI 1.88\u20132.45) and 1.91 (1.73\u20132.10)], with a lower risk of MACE in Class 3 obesity alone (1.29; 1.16\u20131.45). In patients without diabetes, the risk of MACE and death was present in Class 2 and Class 3 obesity but not in those with overweight or Class 1 obesity. Regardless of diabetes status, obesity was less associated with atherosclerotic events than heart failure and renal events. The highest risk for heart failure and renal events was for Class 3 obesity with diabetes [2.92 (2.57\u20133.31) and 3.36 (2.87\u20133.93)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with myocardial infarction, obesity is common and associated with a high risk of mortality, heart failure, and renal events, especially if diabetes is present. There is a need for an increased awareness of this high-risk group with obesity and cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag367","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:55:26Z","timestamp":1783770926000},"source":"Crossref","is-referenced-by-count":0,"title":["Obesity and cardiovascular outcomes after myocardial infarction: a nationwide SWEDEHEART analysis by diabetes status"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-4777","authenticated-orcid":false,"given":"Viveca","family":"Ritsinger","sequence":"first","affiliation":[{"name":"Division of cardiology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Research and Development, Region Kronoberg , V\u00e4xj\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lagerqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-0132","authenticated-orcid":false,"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Division of cardiology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Capio S:t G\u00f6rans Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026081003072696200_zwag367-B1","volume-title":"World Obesity Atlas 2025","author":"World Obesity Federation","year":"2025"},{"key":"2026081003072696200_zwag367-B2"},{"key":"2026081003072696200_zwag367-B3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"},{"key":"2026081003072696200_zwag367-B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081003072696200_zwag367-B5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc25-SINT","article-title":"Standards of care in diabetes, 2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026081003072696200_zwag367-B6","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.jacadv.2025.101644","article-title":"Prevalence and impact of obesity in patients with diabetes and myocardial infarction: a SWEDEHEART Registry Report","volume":"4","author":"Ritsinger","year":"2025","journal-title":"JACC Adv"},{"key":"2026081003072696200_zwag367-B7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","journal-title":"N Engl J Med"},{"key":"2026081003072696200_zwag367-B8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","article-title":"The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study","volume":"371","author":"Li","year":"2008","journal-title":"Lancet"},{"key":"2026081003072696200_zwag367-B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026081003072696200_zwag367-B10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081003072696200_zwag367-B11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026081003072696200_zwag367-B12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12933-024-02365-1","article-title":"Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease","volume":"23","author":"Ritsinger","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026081003072696200_zwag367-B13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the U.S.-the case of SGLT2 inhibitors: Nationwide Cohort Study","volume":"21","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"2026081003072696200_zwag367-B14","first-page":"i","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2026081003072696200_zwag367-B15"},{"key":"2026081003072696200_zwag367-B16"},{"key":"2026081003072696200_zwag367-B17","first-page":"1332","article-title":"The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed","volume":"46","author":"Norhammar","year":"2025","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B18","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"key":"2026081003072696200_zwag367-B19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026081003072696200_zwag367-B20","doi-asserted-by":"crossref","first-page":"e002328","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328","article-title":"High event rate after a first percutaneous coronary intervention (PCI) in patients with diabetes. Results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"8","author":"Ritsinger","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2026081003072696200_zwag367-B21","first-page":"1926","article-title":"Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden","volume":"38","author":"Rosengren","year":"2017","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehaf645","article-title":"Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?","volume":"47","author":"Packer","year":"2026","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"2026081003072696200_zwag367-B24","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081003072696200_zwag367-B26","doi-asserted-by":"crossref","first-page":"770375","DOI":"10.3389\/fphys.2022.770375","article-title":"Aldosterone-regulated sodium transport and blood pressure","volume":"13","author":"Tsilosani","year":"2022","journal-title":"Front Physiol"},{"key":"2026081003072696200_zwag367-B27","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1152\/ajpendo.00115.2010","article-title":"Systemic inflammation activates the nuclear factor-kappaB regulatory pathway in adipose tissue","volume":"299","author":"Ekstr\u00f6m","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026081003072696200_zwag367-B28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1186\/s12864-024-10851-9","article-title":"Characteristics of gene expression in epicardial adipose tissue and subcutaneous adipose tissue in patients at risk for heart failure undergoing coronary artery bypass grafting","volume":"25","author":"Frisk","year":"2024","journal-title":"BMC Genomics"},{"key":"2026081003072696200_zwag367-B29","doi-asserted-by":"crossref","first-page":"220263","DOI":"10.1183\/20734735.0263-2022","article-title":"Respiratory complications of obesity: from early changes to respiratory failure","volume":"19","author":"Shah","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026081003072696200_zwag367-B30","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B31","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/eurheartj\/ehaa398","article-title":"The obesity paradox in secondary prevention: a weighty intervention or a wait for more evidence?","volume":"41","author":"Sattar","year":"2020","journal-title":"Eur Heart J"},{"key":"2026081003072696200_zwag367-B32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ijo.2017.259","article-title":"Journals should no longer accept \u2018obesity paradox\u2019 articles","volume":"42","author":"Peeters","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"2026081003072696200_zwag367-B33","doi-asserted-by":"crossref","first-page":"e069770","DOI":"10.1136\/bmjopen-2022-069770","article-title":"Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006\u20132019: a registry-based cohort study","volume":"13","author":"Leosdottir","year":"2023","journal-title":"BMJ Open"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag367\/68796195\/zwag367.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag367\/68796195\/zwag367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:07:37Z","timestamp":1786345657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag367\/8734280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag367","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"zwag367"}}